Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Incorporating Agents that Target HER2 in the Neoadjuvant Setting

Incorporating Agents that Target HER2 in the Neoadjuvant Setting Neoadjuvant treatment of patients with HER2-positive breast cancer has shown a tremendous success during the last decade since anti-HER2-targeted agents were added to conventional chemotherapy regimen. Efficacy determined by pathological complete response (pCR) increased from approximately 17% with chemotherapy alone to 40% with the addition of trastuzumab, and up to 75% when a dual blockage of the HER2 receptor was achieved by combining chemotherapy with trastuzumab and lapatinib or pertuzumab. pCR rates are higher in hormone receptor–negative tumors. No other predictor for the effect of neoadjuvant anti-HER2 agents on a pCR is validated. In general, patients with a pCR after chemotherapy and trastuzumab showed a highly favorable outcome, whereas patients without a pCR are at high need for additional treatment options. Similar observations for the addition of lapatinib or pertuzumab are awaited. However, recent data suggest that pCR might not be a surrogate for long-term outcome for patients with HER2-positive/hormone receptor–positive tumors. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Breast Cancer Reports Springer Journals

Incorporating Agents that Target HER2 in the Neoadjuvant Setting

Download PDF
7 pages

Loading next page...
 
/lp/springer-journals/incorporating-agents-that-target-her2-in-the-neoadjuvant-setting-xewlSDgCHQ

References (39)

Publisher
Springer Journals
Copyright
Copyright © 2011 by Springer Science+Business Media, LLC
Subject
Medicine & Public Health; Surgical Oncology; Internal Medicine; Oncology
ISSN
1943-4588
eISSN
1943-4596
DOI
10.1007/s12609-011-0054-4
Publisher site
See Article on Publisher Site

Abstract

Neoadjuvant treatment of patients with HER2-positive breast cancer has shown a tremendous success during the last decade since anti-HER2-targeted agents were added to conventional chemotherapy regimen. Efficacy determined by pathological complete response (pCR) increased from approximately 17% with chemotherapy alone to 40% with the addition of trastuzumab, and up to 75% when a dual blockage of the HER2 receptor was achieved by combining chemotherapy with trastuzumab and lapatinib or pertuzumab. pCR rates are higher in hormone receptor–negative tumors. No other predictor for the effect of neoadjuvant anti-HER2 agents on a pCR is validated. In general, patients with a pCR after chemotherapy and trastuzumab showed a highly favorable outcome, whereas patients without a pCR are at high need for additional treatment options. Similar observations for the addition of lapatinib or pertuzumab are awaited. However, recent data suggest that pCR might not be a surrogate for long-term outcome for patients with HER2-positive/hormone receptor–positive tumors.

Journal

Current Breast Cancer Reports – Springer Journals

Published: Sep 6, 2011

There are no references for this article.